What is the true cost of the UK state pension?

To get a sense of the true value of the state pension, you can look at how much you would need to save to match it yourself

TG Therapeutics, Inc. (TGTX)

NasdaqCM - NasdaqCM Real-time price. Currency in USD

Add to watchlist

14.10

+0.32

(+2.32%)

At close: 04:00PM EDT

14.12

+0.02

(+0.14%)

After hours:

07:58PM EDT

Full screen

Trade prices are not sourced from all markets

Previous close	13.78
Open	13.98
Bid	14.09 x 1000
Ask	14.13 x 1000
Day's range	13.65 - 14.31
52-week range	6.46 - 35.67
Volume	2,236,421
Avg. volume	3,493,766

Market cap	2.177B
Beta (5Y monthly)	2.32
PE ratio (TTM)	156.67
EPS (TTM)	0.09
Earnings date	29 Apr 2024 - 03 May 2024
Forward dividend & yield	N/A (N/A)
Ex-dividend date	N/A
1y target est	30.43

All

News

Press releases

GlobeNewswire
TG Therapeutics Announces Additional Data Presentations for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting
NEW YORK, April 18, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced two additional data presentations from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the 2024 American Academy of Neurology (AAN) annual meeting, being held in Denver, Colorado. Links to the data presented yesterday are included below. Michael S. Weiss, Chief Executive Officer and Chairman of TG Therapeutic
GlobeNewswire
TG Therapeutics Awarded National Contract by the Department of Veterans Affairs for BRIUMVI as the Preferred Anti-CD20 for Relapsing Forms of Multiple Sclerosis
NEW YORK, April 18, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), announced that it has been awarded a national contract with the Department of Veterans Affairs (VA) for BRIUMVI® (ublituximab-xiiy) to be the preferred agent listed on the VA National Formulary for Anti-CD20 Antibody indications for patients with relapsing forms of multiple sclerosis (RMS). Michael S. Weiss, Chief Executive Officer and Chairman of TG Therapeutics stated, “We are immensely proud to collaborate with
GlobeNewswire
TG Therapeutics Announces Presentation of Data for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting
NEW YORK, April 15, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentation of data from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the 2024 American Academy of Neurology (AAN) annual meeting, being held in Denver, Colorado. A link to the data presented yesterday is included below. Two additional presentations will be shared on Wednesday April 17, 2024. Michael

FTSE 1008,067.19+43.32(+0.54%)

FTSE 25019,631.50+32.11(+0.16%)

AIM750.15+0.97(+0.13%)

GBP/EUR1.1582-0.0007(-0.06%)

GBP/USD1.2346-0.0004(-0.03%)

Bitcoin GBP53,749.33+128.37(+0.24%)

What is the true cost of the UK state pension?

TG Therapeutics, Inc. (TGTX)

TG Therapeutics Announces Additional Data Presentations for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting

TG Therapeutics Awarded National Contract by the Department of Veterans Affairs for BRIUMVI as the Preferred Anti-CD20 for Relapsing Forms of Multiple Sclerosis

TG Therapeutics Announces Presentation of Data for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting

FTSE 100
8,067.19
+43.32(+0.54%)

FTSE 250
19,631.50
+32.11(+0.16%)

AIM
750.15
+0.97(+0.13%)

GBP/EUR
1.1582
-0.0007(-0.06%)

GBP/USD
1.2346
-0.0004(-0.03%)

Bitcoin GBP
53,749.33
+128.37(+0.24%)